These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37196643)

  • 21. Off-the-Shelf Allogeneic T Cell Therapies for Cancer: Opportunities and Challenges Using Naturally Occurring "Universal" Donor T Cells.
    Perez C; Gruber I; Arber C
    Front Immunol; 2020; 11():583716. PubMed ID: 33262761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Development of allogeneic CAR T-cells].
    Alcazer V; Depil S
    Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD19-chimeric antigen receptor-invariant natural killer T cells transactivate NK cells and reduce alloreactivity.
    Wesle A; Moraes Ribeiro E; Schairer R; Keppeler H; Korkmaz F; Radszuweit P; Bieber K; Lengerke C; Schneidawind D; Schneidawind C
    Cytotherapy; 2024 Aug; ():. PubMed ID: 39269404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TCR-independent Activation in Presence of a Src-family Kinase Inhibitor Improves CAR-T Cell Product Attributes.
    Lamture G; Baer A; Fischer JW; Colon-Moran W; Bhattarai N
    J Immunother; 2022 Apr; 45(3):139-149. PubMed ID: 34802014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
    Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
    Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
    Poirot L; Philip B; Schiffer-Mannioui C; Le Clerre D; Chion-Sotinel I; Derniame S; Potrel P; Bas C; Lemaire L; Galetto R; Lebuhotel C; Eyquem J; Cheung GW; Duclert A; Gouble A; Arnould S; Peggs K; Pule M; Scharenberg AM; Smith J
    Cancer Res; 2015 Sep; 75(18):3853-64. PubMed ID: 26183927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Off-the-Shelf" Allogeneic CAR Cell Therapy-Neglected HvG Effect.
    An Y; Jin X; Zhang H; Zhang M; Mahara S; Lu W; Zhao M
    Curr Treat Options Oncol; 2023 May; 24(5):409-441. PubMed ID: 37010679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells.
    Juillerat A; Tkach D; Yang M; Boyne A; Valton J; Poirot L; Duchateau P
    Front Bioeng Biotechnol; 2020; 8():678. PubMed ID: 32671047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
    Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
    Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
    [No Abstract]   [Full Text] [Related]  

  • 33. Combining CRISPR-Cas9 and TCR exchange to generate a safe and efficient cord blood-derived T cell product for pediatric relapsed AML.
    Lo Presti V; Meringa A; Dunnebach E; van Velzen A; Moreira AV; Stam RW; Kotecha RS; Krippner-Heidenreich A; Heidenreich OT; Plantinga M; Cornel A; Sebestyen Z; Kuball J; van Til NP; Nierkens S
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of Allogeneic CAR T Cells through Specific Degradation of the T Cell Antigen Receptor by E3 Ubiquitin Ligase Fusion Proteins.
    Harris MJ; Chen H; Cai T; Yi Y; Deng Q; Yao Y; Lan T; Guo Y; Xu X; Wen X; McGee JE; Tatang D; Brock J; Shi F; Zhou L
    ACS Synth Biol; 2022 Jun; 11(6):2029-2035. PubMed ID: 35549091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
    Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
    PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transplantation in the onco-hematology field: focus on the manipulation of αβ and γδ T cells.
    Daniele N; Scerpa MC; Caniglia M; Bernardo ME; Rossi C; Ciammetti C; Palumbo G; Locatelli F; Isacchi G; Zinno F
    Pathol Res Pract; 2012 Feb; 208(2):67-73. PubMed ID: 22115749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation.
    Locatelli F; Bauquet A; Palumbo G; Moretta F; Bertaina A
    Immunol Lett; 2013; 155(1-2):21-3. PubMed ID: 24091162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
    Lahimchi MR; Maroufi F; Maali A
    Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
    Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
    Front Immunol; 2021; 12():686439. PubMed ID: 34616392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Advances in Allogeneic Chimeric Antigen Receptor T Cells].
    Zhao Q; Li F
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Dec; 45(6):967-972. PubMed ID: 38173109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.